Hypertension specific patient-reported outcome measure. Part II: validation survey and item selection process

Ionov M. V.^{1,2}, Zvartau N. E.^{1,2}, Dubinina E. A.^{3,4}, Khromov-Borisov N. N.¹, Konradi A. O.^{1,2}

Aim. Improvement of the health-related quality of life (HRQoL) is one of the basic principles of value-based medicine. HRQoL could be assessed by the patient reported outcome measures (PROMs) also in case of arterial hypertension (HTN). However for HTN patients only generic PROMs are still used. Previously the group of experts had created the primary version of HTN-specific PROM. The purpose of the second part was to conduct a validation survey and to select the items in a statistically-based manner.

Material and methods. Validation survey was conducted in a large multidisciplinary center among patients with HTN stages 1-3 and healthy volunteers. Inclusion criteria were age >18 years old, ability to understand or complete the scale themselves, absence of significant illness requiring hospitalization. The items were selected according to the principles of classical test theory (CTT) and item response theory (IRT). The criteria for CTT were sensitivity (standard deviation and coefficient of variation with corresponding confidence intervals), representativeness (item-total Pearson's correlation coefficient), internal consistency (Cronbach's α coefficient). In IRT analysis two methods were adopted - value of four degrees of difficulty and the discrimination estimate. Each question was evaluated according to 8 criteria. An item was considered for selection when it was retained by ≥ 4 criteria. The expert panel considered practical significance of each item.

Results. A total of 430 questionnaires were distributed and 407 (94,7%) of them were returned completed (from 359 hypertensive patients, mean age $62,3\pm11,7$ y.o.; 48 healthy volunteers, mean age $38,8\pm10,5$ y.o.). The average time for PROM filling was $24\pm4,2$ minutes. Of 163 questions, 27 met all 8 criteria and 3 questions did not match any of the 36 HTN-specific questions, 11 matched \geq 5 criteria and in the generic part there were 87 questions (33 in the PHY domain, 35 for PSY, 8 for SOC, 11 for THER). The symmetric distribution of criteria was seen in 25 questions, of which 11 were evaluated by experts and then retained. For 40 questions, <4 eligibility

criteria were recorded, of which 9 were retained after expert review. The PROM draft contained 80 questions (19 questions in the physiology domain, 22 in psychology, 6 in social, 13 in therapy, 20 items are HTNspecific).

Conclusion. The methods of CTT and IRT allowed to reduce the PROM volume without losing the semantic richness and the need to reorganize the conceptual structure. The next step is the validation of the scale.

Key words: arterial hypertension, patient-reported outcome measures, health related quality of life, questionnaire, classical test theory, item response theory.

Conflicts of interest: nothing to declare.

Funding. The study was conducted by a grant from the Russian Science Foundation (project № 17-15-01177).

¹Almazov National Medical Research Center, St. Petersburg; ²St. Petersburg National Research University of Information Technologies, Mechanics and Optics (ITMO University), St. Petersburg; ³A. I. Herzen Russian State Pedagogical University, St. Petersburg; ⁴V. M. Bekhterev National Medical Research Center of Psychiatry and Neurology, St. Petersburg, Russia.

Ionov M. V.* ORCID: 0000-0002-3664-5383, Zvartau N. E. ORCID: 0000-0001-6533-5950, Dubinina E. A. ORCID: 0000-0003-1740-6659, Khromov-Borisov N. N. ORCID: 0000-0001-6435-7218, Konradi A. O. ORCID 0000-0001-8169-7812.

*Corresponding author: ionov_mv@almazovcentre.ru

Received: 14.04.2019 Revision Received: 17.05.2019 Accepted: 24.05.2019

CC BY 4.0

For citation: Ionov M. V., Zvartau N. E., Dubinina E. A., Khromov-Borisov N. N., Konradi A. O. Hypertension specific patient-reported outcome measure. Part II: validation survey and item selection process. *Russian Journal of Cardiology*. 2019;(7):40-46. (In Russ.) doi:10.15829/1560-4071-2019-7-40-46

Hypertension (HTN) as the leading cause of premature mortality and disability [1], is predicted to maintain a leading position until 2040 [2]. Undoubtedly, the main aim of health care is to save and prolong life. However, improving of life quality (reduce the severity of symptoms, lighten the psychological and social burden of diseases) is equally important. Like most chronic pathologies, HTN affects the quality of life (QOL) associated with health in the range from insignificant to quite significant [3]. This fact is of particular interest since there are more than a billion HTN patients around the world, the effectiveness of treatment in most of which is insufficient [4].

Recent scientific evidence detects a decrease in QOL of patients with uncontrolled HTN; however, even with undoubted effectiveness of some antihypertensive drugs and rational treatment regimens, it can also negatively affect QOL [5]. To "measure" the symptoms and influence of the disease on the psychological, social fields of the patient's life is possible due to patient-reported outcome measures (PROMs) — a highly effective tool for translating subjective perception into an objective assessment.

Since the use of PROMs in routine clinical practice allows you to change the paradigm of decision taking, making it more personalized, it is expected that medical care can be better also at population level. Thus, international and Russian guidelines for the management of HTN patients are general in nature and are based on the "crude" stratification of patients according to the main objective parameters [6]. In turn, PROMs is a more holistic and comprehensive assessment of QOL and the treatment effect from the patient's point of view. PROMs analysis can provide the doctor with valuable information for implementing the precision medicine. It is also worth noting that sometimes the results of PROMs analysis are the primary endpoints of clinical trials, replacing or complementing the "conventional" objective and laboratory goals.

Detailed algorithms for developing tools of QOL assessing are given in the international guidelines. However, many researchers have noted the difficulties in choosing a suitable PROM, since it often depends on a specific pathology, clinical trial and goals of the authors/experts. As with many chronic pathologies, patients with HTN are in a certain conditions' continuum, determined by the degree of severity (which can be significantly alleviated in a short time) and stage (almost unman-

ageable). Therefore, it is important to have reliable and concise questionnaires for patients with a certain pathology. In addition, using adequate data obtained with the help of disease-specific PROMs, it becomes possible to carry out cost-utility analysis [7]. It is one of the most complex and sophisticated methods of economic analysis, which is most important in the value-based healthcare (clinical, economic and patient-oriented benefits).

At first stage, the process of creating a multidimensional and multivariate disease-specific PROM for HTN patients was described [8]. As the first part of study, Interviewing and pilot questioning of patients were carried out, followed by assessment of the questionnaire structure, which greatly reduced it. The current stage is aimed at use of special statistical methods for the analysis of psychological tests, which complement the qualitative examination.

Material and methods

The study was conducted in accordance with the Good Clinical Practice standards and Declaration of Helsinki principles. The study protocol was approved by the local Ethics Committee. Prior to inclusion in the study, all participants gave written informed consent. The guidelines and documents of Food and Drug Administration (FDA) [9], the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [10], and the International Society for Quality of Life Research (ISO-QOL) were used for PROM creation and validation [11]. The study was supported by a grant from the Russian Science Foundation (project N 17-15-01177).

Validation study. The survey with the primary PROM version [8] was conducted in an outpatient department of a large multidisciplinary medical center.

The main group consisted of patients with stage 1-3 HTN who were first seen by a hypertensiologist (one of the authors), while the antihypertensives' status was not taken into account. The second group of participants was conditionally healthy volunteers.

The general inclusion criteria were at least 18 years of age, the ability to understand the purpose and instructions for filling out, independently read and answer the questions in the print PROM form.

The main exclusion criteria were a cognitive deficit assessed by a physician subjectively or a diagnosis of grade 2 or higher encephalopathy, a serious somatic pathology (cardiovascular or non-



Fig. 1. The design of the second stage of the PROM development for HTN patients.

Abbreviations: PROM — patient-reported outcome measure, HTN — hypertension, CTT — classical test theory, IRT — item response theory, CI — confidence interval.

cardiac), which required hospital (including surgical) treatment in the near future. All participants were asked to fill out a questionnaire after talking with a doctor and completing an informed consent form.

Statistical analysis. The selection of questions was based on the classical test theory (CTT) and item response theory (IRT).

When selecting questions by CTT, the following 6 criteria were used:

1. The sensitivity of the item was determined by standard deviation (SD). A question considered inappropriate if SD was <1,0.

1.1. Values of 95% confidence interval (CI) of SD >1,0 was the criterion of acceptability. Preferably, the lower confidence limit meets these requirements.

2. A question sensitivity was also evaluated using the coefficient of variation (CV) of responses;

CV > 20 units was required to remain question in the intermediate questionnaire version.

2.1. Similar to the CI for SD, the same requirements were used on the 95% CI for CV; the lower confidence limit was supposed to be >20 units.

3. Question representativeness was evaluated based on the item-total correlation. A question was considered appropriate if the Pearson's correlation coefficient between the mean value of the responses of a question and its area exceeded the CV=0.5.

4. Internal consistency was determined by Cronbach's alpha, which should have exceeded 0,5.

When selecting questions by IRT, 2 criteria were used, the values of which were estimated by maximum likelihood method:

1. Discrimination estimate (coefficient a). The key principle was as follows: the higher the coefficient a, the higher the item informative value. If the coefficient value exceeded the a>0,5, then a question was remained in the questionnaire.

2. Value of difficulty degree, determined by four coefficients b1, b2, b3 and b4 and satisfying the inequality b1 < b2 < b3 < b4. In this case, the values of b1 and b4 should have been in the range from -3 to +3. Questions where the values of these items fell outside this range, was removed from the questionnaire, since the distribution of answers to them would be shifted to one of the extremes (responses with points 1 or 5).

Each question was evaluated based on the eight criteria described above. If an item meets with four or more ones, then it could be maintain in the questionnaire. In addition, the significance and semantic richness of a question were reassessed by expert group. Thus, with the both use of statistical analysis and expert review, the logic and informative value of the second intermediate PROM version were formed (Fig. 1).

Statistical processing of the results was performed using the non-profit open source software package R Statistics (ver. 3.1.0, The R Foundation for Statistical Computing, Vienna, Austria) and the SPSS software package (ver. 23.0, IBM, Chicago, IL, USA). The level of statistical significance for differences was set as p<0,05. The following specialized programs were also used: IRTShiny Version 1.1 (http://kylehamilton.net/shiny/IRT-Shiny/); Classical Test Theory (Item Analysis) – http: //kylehamilton.net/shiny/CTTShiny. The jamovi software (https://www.jamovi.org/) was used for the reliability analysis.

Results

The questionnaire survey involved 430 people. Overall 407 participants completed PROM forms: 359 - HTN patients: mean age $- 62,3 \pm 11,7$ years, 56,8% — women; stage 1 HTN — 139 patients, stage 2 HTN - 136 patients, stage 3 HTN - 84 patients; 48 — healthy volunteers (mean age — $38,8\pm10,5$ years, 70,8% — women). The questionnaire completion rate was 94,7%, and the average completion time was $24\pm4,2$ minutes (for HTN patients, since healthy volunteers did not answer questions regarding treatment). All respondents who completed the questionnaire and who were able to conduct a post-test interview (n=128), informed the clinical investigator that the questions and response options were correctly formulated and did not cause difficulties.

Analysis of the frequency distribution showed that there were 11,4% of unanswered questions.

The missing data was analyzed by the Little's Test of Missing Completely at Random: $\chi^2=347$, p=0,39. Results showed that the distribution is consistent with normal, and omissions are random. Missing data was recovered by multiple imputation method.

The initial version of the questionnaire, formed by conceptual framework, consisted of a general ("non-specific") part, which included areas of "physiology" (PHY) with 43 questions (5 subareas: physical symptoms, general well-being and vitality, self-assessment, the limiting effect of physical health, dynamics of physical health), "psychology" (PSY) with 42 questions (5 subareas: emotional and behavioral symptoms, cognitive symptoms, psychological well-being, the limiting effect of mental health, dynamics of mental health). General part also included "social" area (SOC), which contained 15 questions (4 sub-area: social frustration, social resources, the effect of physical and mental health on social activity), and the "therapy" domain (THER) with 27 items (6 sub-areas: therapy satisfaction, therapy-related physical changes, therapy-related psychological changes, the effect of the treatment regimen on daily life, adherence to treatment). HTN-specific part included 13 questions in PHY and THER subdomains similar to the general part, 4 questions in PSY and 6 in SOC subdomains).

Thus, a total of 163 questions were assessed (36 questions regarded only HTN). For each question, the CTT and IRT criteria values are presented in Table 1. Twenty seven questions met all 8 criteria (2 questions of HTN-specific, 20 in the PHY area, 4 in the PSY area, 1 in the SOC area). Despite satisfactory values, questions PHY 4 3, PHY 4 5, and PHY 4 8 were removed due to low practical PHY 4 10 significance, questions and PHY 4 12 – due to duplication. PHY 4 14 and PHY 4 17 questions were not included in the intermediate version because similar questions were in the HTN-specific part (HTN SOC 5, HTN SOC 7, respectively). The following three questions did not meet any of the criteria: THER 6 7 "How often do you take medicine on friend recommendations or on your own without prescription?", THER_7_1 "How often do you miss scheduled appointments with a doctor?", HTN_THER_14 "How often do you eat fast food. These questions were excluded from the intermediate version of the questionnaire.

Eleven questions of the HTN-specific part met ≥ 5 criteria; there were 87 such items in the gen-

eral part (33 were in the PHY domain, 35 - in the PSY area, 8 - in the SOC area, 11 - in the THER domain). After consistent expert review, 3 questions were removed from the HTN-specific part (HTN SOC 4, HTN THER 10, HTN THER 11) due to low practical significance. In addition to the already mentioned items. 28 following ones were excluded from the general part: 7 PHY questions (practical insignificance, duplication of the HTN-specific part, discrepancy with the HTN concept), 15 PSY questions (low reliability, practical insignificance), 3 SOC questions (practical insignificance, duplication of the HTN-specific part); 3 THER questions (practical insignificance, duplication of the HTN-specific part).

Symmetric distribution of criteria was observed in 25 questions (9 – HTN-specific). These questions were reassessed by the authors, as a result of which 11 ones (HTN – 5, PSY – 1, THER – 5 questions) were remained in the intermediate version (due to the semantic richness and practical significance).

Forty questions did not meet at least 4 criteria (except for the three questions described above); 9 of them were remained after an expert review due to practical significance $(7 - \text{HTN-specific, questions PSY}_5 - 5$ and SOC_1_1 in the relevant areas).

Forty six questions (21 - HTN-specific) did not meet both basic statistical criteria of CTT and IRT (reliability and difficulty, respectively). Only 16 of them were remained in in the intermediate version of the questionnaire (11 - HTN-specific, 2 - PSY and THER, 1 - SOC) due to their practical significance and semantic richness.

Due to significant reduction of question pool and to facilitate the validation, HTN-specific questions were integrated into the relevant areas of the general part. Thus, the questions HTN PHY 1-12 remained in the sub-area "physical symptoms"; items HTN PSY 1-4 constituted an additional sub-area of "hypo- and hypernosognosia" in the PSY domain; HTN SOC 3 were added to the sub-area "social resources in the HTN treatment", and questions HTN SOC 5,7 – to the sub-area "the effect of physical health on social activity"; questions HTN THER 1,2 were included in the subdomain "therapy satisfaction", HTN THER 3-5 were included in the subdomain "adherence to treatment". The sub-areas "dynamics of physical health", "the effect of mental health on social activity" were removed from the interme-

diate version of PROM. As a result, the intermediate version included 80 questions (19 - PHY, 22 - PSY, 6 - SOC, 13 - THER, and 20 HTNspecific items) (Annex 1).

Discussion

Expert selection, creating a conceptual framework and developing a questionnaire are some of the most important and difficult steps. However, when these steps are taken, it becomes necessary to select meaningful, practically significant, most reliable questions. An important step in the second part of the study was the need to obtain a sufficient amount of data for statistical analysis.

The most common method of social and psychological research is a mass survey. This is particularly important when developing new PROM or adapting well-known foreign-language ones, since the contribution of patients and the subsequent interviewing is one of the ways to confirm content validity [9]. Therefore, HTN patients, especially ambulatory ones, were broadly covered in the conditions close to the real clinical practice. Nevertheless, the mass survey inevitably leads to incomplete data, which is often associated with the unattainability, fatigue or inattention (when completing large questionnaires), cultural, ethnic and social characteristics of individuals [12]. The main reason for the loss of a tenth of the required data, according to the Little's MCAR test, was the fatigue or inattention of the respondents.

The resulting data pool of responses became the basis for evaluating each unit of the HTN-specific PROM according to both CTT and IRT.

CTT methods, also called true score theory, are clear and readily available for use. The main criteria of CTT in this work were considered SD and reliability. It should be noted that the authors did not evaluate the factor loading due to the large number of questions, areas and sub-areas. So, the probability of unreliable distribution by factors was rather high. For the Hyper-PRO questionnaire, an exploratory factor analysis was carried out within the initial selection of questions [13]. That was reasonable due to small initial pool.

It should be noted that despite the CTT recognition, it does not take into account latent traits and abilities of the respondents, and therefore the reliability assessment may be inadequate. In addition to CTT, an IRT method was used, based on item characteristics curves and difficulty of questions. CTT has three advantages over IRT: the assessment of respondent's capacity does not depend on a specific question; the assessment does not depend on the study population; the accuracy of capacity assessment can also be determined. When using CTT, it is possible to determine the nonlinear relationship between the respondent's response and its potential quality, or to describe the relationship between the response and the factor underlying the question. However, CTT principles are rather difficult to understand and therefore the application is limited mainly by the teaching tests [14].

Reliability, size and content are important characteristics affecting the CTT application for PROM development. There is a growing understanding among specialists that combinations of quality questions can contribute to the development of the most valid and concise PROMs that would reduce the "respondent burden". Therefore, attempts are being made not to evaluate the PROM as a holistic concept, but to determine the reliability and importance of questions based on the characteristics of the patients' response. The active introduction of CTT and computer programs for adaptive testing made it possible to create a PROMIS system (Patient-Reported Outcomes Measurement Information System). From a large database of questions, a small number of the most informative items are selected based on the patient's characteristics. [15].

Most of the questions were removed on the basis of CTT and IRT combination. However, the items that were significant for the overall structure, despite that some of them did not meet the criteria, were remained based on the expert review. For example, most of the inappropriate questions of the HTN-specific part were remained, and the questions of the last THER subdomain (in the general and HTN-specific parts) were excluded; the sub-area "adherence to treatment" was significantly reduced. Items of this area were developed based on the clinical judgment of the authors and the theoretical problems of treating HTN patients. Probably, cultural, sociological and age-related characteristics, along with sample bias could be associated with the insufficient compliance with the selection criteria.

Conclusion

The development of a disease-specific questionnaire based on the outcomes reported by HTN patients passed the second stage using the CTT and IRT methods and expert review. The results obtained led to its twofold reduction due to the exclusion of inappropriate (duplicate, unreliable, difficult to understand) items. In addition, the prior structure and conceptual framework have been remained in the intermediate PROM version. The next step is to analyze validity, reliability and sensitivity.

Funding. The study was conducted by a grant of the Russian Science Foundation (project \mathbb{N}° 17-15-01177).

Conflicts of Interest: nothing to declare.

References

- GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Lond Engl. 2018;392:1923-94. doi:10.1016/S0140-6736(18)32225-6.
- Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. The Lancet. 2018;392:2052-90. doi:10.1016/S0140-6736(18)31694-5.
- Trevisol DJ, Moreira LB, Kerkhoff A, et al. Health-related quality of life and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2011;29:179-88. doi:10.1097/ HJH.0b013e328340d76f.
- Forouzanfar MH, Liu P, Roth GA, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317:165-82. doi:10.1001/jama.2016.19043.
- Youssef RM, Moubarak II, Kamel MI. Factors affecting the quality of life of hypertensive patients. East Mediterr Health J Rev Sante Mediterr Orient Al-Majallah Al-Sihhiyah Li-Sharq Al-Mutawassit. 2005;11:109-18.
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-104. doi:10.1093/eurheartj/ehy339.
- Yagudina RI, Sorovikov IV. Methodology of Cost-Utility Analysis in Pharmacoeconomic Studies. Farmakoekonomika. Modern Pharmacoeconomic and Pharmacoepidemiology. 2012;5:9-12. (In Russ.)
- Ionov MV, Zvartau NE, Dubinina EA, et al. Hypertension specific patient-reported outcome measure. Part I: development and primary evaluation Russ J Cardiol. 2019;24(6):54-60. (In Russ.) doi:10.15829/1560-4071-2019-6-54-60.

- US Department of Health and Human Services (USDHHS). Guidance for industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. https:// www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-productdevelopment-support-labeling-claims (13 April 2019).
- Eremenco S, Coons SJ, Paty J, et al. PRO data collection in clinical trials using mixed modes: report of the ISPOR PRO mixed modes good research practices task force. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2014;17:501-16. doi:10.1016/j.jval.2014.06.005.
- 11. Reeve BB, Wyrwich KW, Wu AW, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2013;22:1889-905. doi:10.1007/s11136-012-0344-y.
- Pedersen AB, Mikkelsen EM, Cronin-Fenton D, et al. Missing data and multiple imputation in clinical epidemiological research. Clin Epidemiol. 2017;9:157-66. doi:10.2147/CLEP.S129785.
- Zhi L, Qiaojun L, Yanbo Z. Development and validation of patientreported outcomes scale for hypertension. Int J Qual Health Care J Int Soc Qual Health Care. 2015;27:369-76. doi:10.1093/intqhc/ mzv060.
- 14. Bock RD. A Brief History of Item Theory Response. Educ Meas Issues Pract 1997;16:21-33. doi:10.1111/j.1745-3992.1997.tb00605.x.
- Bjorner JB, Rose M, Gandek B, et al. Difference in method of administration did not significantly impact item response: an IRTbased analysis from the Patient-Reported Outcomes Measurement Information System (PROMIS) initiative. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2014;23:217-27. doi:10.1007/s11136-013-0451-4.

| | | Sum | mary o | f question s | selectic | n accol | ding to | o the c | riteria of cla | assical tes | st theory an | d item resp | onse theory | _ | |
|------------|------|-----------------------------------|-----------------------------------|--------------------------|-----------------------------------|-----------------------------------|---------|---------|------------------------|-----------------|--------------|---------------------|------------------------------|----------|-----------------------------|
| Question | SD | Lower confi- dence limit | Upper confi- dence limit | Coefficient of variation | Lower confi- dence limit | Upper confi- dence limit | TT3_b1 | TT3_b4 | TT3_ discriminant_A | Cronbach's α | Pearson's r | Met the criteria | Did not meet the criteria | Selected | Comments |
| HTN_PHY_1 | 1,01 | 0,94 | 1,08 | 27,2 | 24,8 | 29,5 | -6,00 | 1,50 | 0,25 | 0,15 | 0,41 | e | £ | > | practical significance |
| HTN_PHY_2 | 1,02 | 0,95 | 1,08 | 27,8 | 25,6 | 30,0 | -6,50 | 1,40 | 0,27 | 0,21 | 0,44 | e | ى ا | > | practical significance |
| HTN_PHY_3 | 1,04 | 0,97 | 1,10 | 27,9 | 25,7 | 30,1 | -8,30 | 1,50 | 0,24 | 0,06 | 0,30 | З | Ð | > | practical significance |
| HTN_PHY_4 | 1,13 | 1,06 | 1,20 | 31,8 | 29,2 | 34,3 | -3,80 | 1,00 | 0,63 | 0,40 | 0,55 | 9 | 5 | > | |
| HTN_PHY_5 | 1,21 | 1,11 | 1,30 | 32,6 | 29,1 | 36,0 | -4,50 | 0,72 | 0,39 | 0,32 | 0,30 | 4 | 4 | × | practical insignificance |
| HTN_PHY_6 | 0,68 | 0,57 | 0,77 | 14,8 | 12,3 | 17,1 | 0,90 | 0,72 | 0,46 | 0,20 | 0,44 | - | 7 | × | |
| ΗΤΝ_ΡΗΥ_7 | 0,99 | 0,91 | 1,08 | 24,1 | 21,4 | 26,6 | -2,23 | 0,09 | 1,01 | 0,44 | 0,57 | 5 | 3 | > | |
| HTN_PHY_8 | 0,98 | 0,91 | 1,05 | 24,5 | 22,3 | 26,8 | -3,00 | 0,30 | 0,93 | 0,46 | 0,62 | 4 | 4 | > | practical significance |
| ΗΤΝ_ΡΗΥ_9 | 1,10 | 0,98 | 1,20 | 28,2 | 25,0 | 31,2 | -2,86 | 0,43 | 0,85 | 0,47 | 0,61 | 6 | 2 | > | |
| HTN_PHY_10 | 1,09 | 1,01 | 1,16 | 34,9 | 32,0 | 37,8 | -1,10 | 1,30 | 1,30 | 0,51 | 0,67 | 8 | 0 | > | |
| HTN_PHY_12 | 1,06 | 0,99 | 1,13 | 39,4 | 36,2 | 42,7 | 0,56 | 3,20 | 0,89 | 0,37 | 0,50 | 4 | 4 | > | practical significance |
| HTN_PHY_13 | 0,94 | 0,85 | 1,03 | 23,7 | 21,1 | 26,3 | -1,90 | 0,70 | 0,33 | 0,30 | 0,41 | e | Q | × | |
| HTN_PHY_14 | 0,91 | 0,85 | 0,97 | 24,4 | 22,6 | 26,2 | -4,60 | 1,14 | 0,36 | 0,29 | 0,35 | 2 | 9 | × | |

Table 1

| Question | SD | Lower confi- dence limit | Upper confi- dence limit | Coefficient of variation | Lower confi- dence limit | Upper confi- dence limit | TT3_b1 | TT3_b4 | TT3_ discriminant_A | Cronbach's α | Pearson's r | Met the criteria | Did not meet the criteria | Selected | Comments |
|-----------|------|-----------------------------------|-----------------------------------|-----------------------------|-----------------------------------|-----------------------------------|--------|--------|------------------------|-----------------|-------------|---------------------|---------------------------|----------|-----------------------------|
| HTN_PSY_1 | 1,14 | 1,05 | 1,21 | 29,8 | 27,0 | 32,5 | -4,50 | - 1,70 | 0,16 | 0,20 | 0,44 | 4 | 4 | > | practical significance |
| HTN_PSY_2 | 1,42 | 1,35 | 1,49 | 42,5 | 39,1 | 45,9 | -2,52 | 2,80 | 0,08 | 0,20 | 0,74 | 0 | Q | × | practical insignificance |
| HTN_PSY_3 | 1,32 | 1,25 | 1,39 | 45,1 | 41,8 | 48,4 | -0,63 | 1,75 | 0,67 | 0,38 | 0,82 | 7 | + | > | |
| HTN_PSY_4 | 1,35 | 1,29 | 1,42 | 43,6 | 40,5 | 46,9 | -1,49 | 1,12 | 0,54 | 0,50 | 0,43 | 7 | - | > | |

| | | | | e | | | | | | | | | e | | e | e | e | e | | | - the |
|-----------------------------------|-----------|-----------|---------------------------|---------------------------|-----------|-----------|-----------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------|-------------|--------------------|
| Comments | | | practical significance | practical insignifican | | | Comments | practical significance | practical significance | practical significance | practical significance | practical significance | practical insignifican | | practical insignifican | practical insignifican | practical insignifican | practical insignifican | | | CBC b4 - |
| Selected | × | × | > | × | > | > | Selected | > | > | > | > | > | × | × | × | × | × | × | × | × | CBC b1. |
| Did not meet the criteria | ъ 2 | S | Q | ო | 0 | 0 | Did not meet the criteria | CJ | Q | ъ 2 | 4 | 4 | 4 | 6 | 4 | e | e | 4 | 5 | 8 | idence interval. (|
| Met the criteria | ო | ę | m | Ъ | ω | 9 | Met the criteria | m | N | ო | 4 | 4 | 4 | 2 | 4 | IJ | ъ | 4 | ო | 0 | ant CI - conf |
| Pearson's r | 0,54 | 0,68 | 0,55 | 0,43 | 0,66 | 0,68 | Pearson's r | 0,52 | 0,65 | 0,57 | 0,71 | 0,65 | 0,35 | 0,43 | 0,24 | 0,30 | 0,29 | 0,48 | 0,45 | 0,12 | ation coafficie |
| Cronbach's α | 0,49 | 0,44 | 0,36 | 0,17 | 0,50 | 0,52 | Cronbach's α | 0,43 | 0,14 | 0,24 | 0,24 | 0,33 | 0,34 | 0,39 | 0,10 | 0,03 | 0,22 | 0,35 | 0,13 | 0,03 | n-total corral |
| TT3_ discriminant_A | 0,43 | 0,37 | 0,37 | 0,20 | 2,58 | 2,99 | TT3_ discriminant_A | 0,48 | 0,18 | 0,29 | 0,19 | 0,23 | 0,31 | 0,46 | 0,17 | 0,12 | 0,17 | 0,28 | 0,19 | 0,25 | Daareon'e itar |
| TT3_b4 | 1,98 | 1,64 | 1,40 | 0,88 | 0,57 | 1,06 | TT3_b4 | 2,08 | 0,08 | 2,59 | 3,66 | -0,40 | -0,84 | 0,64 | 2,66 | 2,80 | -0,87 | 4,80 | 1,64 | 2,20 | on'e r |
| TT3_b1 | -4,30 | -3,38 | -4,14 | -3,30 | -1,36 | -1,29 | TT3_b1 | -3,34 | -4,14 | -3,04 | -1,55 | -3,46 | -4,97 | -5,85 | -3,30 | 2,40 | -2,82 | -5,40 | -5,37 | -5,80 | n Daare |
| Upper confi- dence limit | 27,6 | 28,5 | 25,0 | 38,7 | 32,3 | 32,6 | Upper confi- dence limit | 23,8 | 24,2 | 24,5 | 27,9 | 27,6 | 30,2 | 26,2 | 36,7 | 62,6 | 30,5 | 36,9 | 29,1 | 18,2 | of variatio |
| Lower confi- dence limit | 22,4 | 23,5 | 20,0 | 31,9 | 27,0 | 27,4 | Lower confi- dence limit | 20,0 | 18,7 | 20,2 | 21,3 | 21,9 | 24,3 | 21,7 | 29,8 | 56,0 | 24,0 | 31,9 | 23,8 | 14,6 | finiont o |
| Coefficient of variation | 25,1 | 26,1 | 22,6 | 35,3 | 29,7 | 30,0 | Coefficient of variation | 21,9 | 21,5 | 22,3 | 24,7 | 24,9 | 27,4 | 24,0 | 33,4 | 59,2 | 27,3 | 34,4 | 26,5 | 16,4 | |
| Upper confi- dence limit | 1,06 | 1,04 | 0,98 | 1,38 | 1,18 | 1,11 | Upper confi- dence limit | 0,89 | 0,99 | 0,92 | 1,15 | 1,10 | 1,19 | 1,03 | 1,31 | 1,34 | 1,19 | 1,23 | 1,10 | 0,80 | Ind doviat |
| Lower confi- dence limit | 0,89 | 0,89 | 0,81 | 1,21 | 1,03 | 0,96 | Lower confi- dence limit | 0,76 | 0,79 | 0,77 | 0,92 | 0,91 | 1,01 | 0,88 | 1,13 | 1,14 | 0,99 | 1,09 | 0,93 | 0,66 | 000040 |
| SD | 0,97 | 0,97 | 0,90 | 1,30 | 1,11 | 1,03 | SD | 0,82 | 0,90 | 0,85 | 1,05 | 1,01 | 1,11 | 0,96 | 1,23 | 1,25 | 1,09 | 1,16 | 1,02 | 0,73 | 20 |
| Question | HTN_SOC_1 | HTN_SOC_2 | HTN_SOC_3 | HTN_SOC_4 | HTN_SOC_5 | HTN_SOC_7 | Question | HTN_THER_1 | HTN_THER_2 | HTN_THER_3 | HTN_THER_4 | HTN_THER_5 | HTN_THER_6 | HTN_THER_7 | HTN_THER_9 | HTN_ THER_10 | HTN THER11 | HTN_ THER_12 | HTN_THER_13 | HTN_THER_14 | Akhrovistions |

| Comments | | | discrepancy with the HTN concept | | discrepancy with the HTN concept | | discrepancy with the HTN concept | | | | | | | | low reliability | Comments | | | | | | | Comments | | duplication of the HTN- specific part | | practical insignificance | |
|---------------------------------|---------|---------|--|---------|--|---------|--|---------|----------|----------|----------|----------|----------|----------|-----------------|------------------------------|---------|---------|---------|---------|----------|----------|------------------------------|---------|---|---------|-----------------------------|---------|
| Selected | × | > | × | > | × | > | × | × | > | > | > | > | × | × | × | Selected | > | > | > | × | × | × | Selected | > | × | > | × | > |
| Did not meet the criteria | 5 | - | e | ო | - | 0 | - | 5 | 0 | - | 0 | 0 | 9 | 4 | 7 | Did not meet the criteria | ÷ | + | 0 | 5 | 4 | 4 | Did not meet the criteria | 0 | - | 0 | - | 0 |
| Met the criteria | e | 7 | Ŋ | ß | 7 | 80 | 7 | e | œ | 7 | œ | œ | 2 | 4 | 6 | Met the criteria | 7 | 7 | 8 | ო | 4 | 4 | Met the criteria | 8 | 7 | 80 | 7 | œ |
| Pearson's r | 0,56 | 0,67 | 0,68 | 0,73 | 0,64 | 0,62 | 0,71 | 0,59 | 0,70 | 0,63 | 0,62 | 0,62 | 0,55 | 0,63 | 0,55 | Pearson's r | 0,80 | 0,82 | 0,72 | 0,59 | 0,59 | 0,62 | earson's r | ,79 | 1,82 | ,83 | ,76 | ,88 |
| Cronbach's α | 0,44 | 0,59 | 0,59 | 0,64 | 0,54 | 0,54 | 0,69 | 0,51 | 0,63 | 0,61 | 0,53 | 0,54 | 0,46 | 0,57 | 0,48 | Cronbach's α | 0,69 | 0,61 | 0,60 | 0,46 | 0,37 | 0,51 | cronbach's F κ | ,629 (|),657 (| ,686 0 | ,567 0 | ,735 0 |
| TT3_ discriminant_A | 0,39 | 0,75 | 1,00 | 1,18 | 0,62 | 0,60 | 0,73 | 1,10 | 0,86 | 0,72 | 0,65 | 0,79 | 0,53 | 0,68 | 0,53 | TT3_ discriminant_A | 0,89 | 0,60 | 0,60 | 0,47 | 0,24 | 0,60 | IT30 | 0,77 0 | 1,11 0 | 1,00 0 | 0,72 0 | 1,21 0 |
| TT3_b4 | 2,3 | 0,2 | -0,4 | -0,8 | 7,9 | -0,4 | 6,5 | 1,77 | -0,72 | -0,6 | 0,56 | 0,6 | -0,1 | -0,23 | -0,27 | TT3_b4 | 1,47 | 2.0 | 0,80 | 0,01 | 4,60 | -0,16 | TT3_b4 | 0,58 (| 0,99 | 1,58 | 2,45 (| 1,56 |
| TT3_b1 | 8- | ကု | -4,4 | -4,1 | ကို | -1,9 | -1,5 | -3,6 | -2 | -3,4 | -2,5 | -2,3 | -3,3 | -4,43 | -3,76 | TT3_b1 | -2,6 | -3,20 | -2,65 | -6,10 | -5,05 | -4,54 | TT3_b1 | -2,70 | -2,63 | -1,81 | -2,30 | -1,63 |
| Upper confi- dence limit | 28,3 | 29,7 | 26,8 | 26,8 | 37,7 | 33,1 | 48 | 18,2 | 32,5 | 34,7 | 35,5 | 30,4 | 19,8 | 24,5 | 30,4 | Upper confi- dence limit | 35,0 | 38, 15 | 43,1 | 25,0 | 33,9 | 26,3 | Upper confi- dence limit | 46,2 | 37,5 | 49,1 | 39,5 | 47,8 |
| Lower confi- dence limit | 23,1 | 23,3 | 21,6 | 22,0 | 32,0 | 26,8 | 41 | 14,6 | 25,4 | 29,1 | 29,0 | 23,6 | 15,1 | 20,0 | 23,9 | Lower confi- dence limit | 29,1 | 32,1 | 35,9 | 20,0 | 28,1 | 21,3 | Lower confi- dence limit | 39,8 | 31,6 | 42,7 | 32,7 | 41,3 |
| Coefficient of variation | 25,8 | 26,5 | 24,4 | 24,5 | 34,9 | 30,4 | 45 | 16,7 | 29,0 | 31,9 | 32,3 | 27,2 | 17,6 | 22,1 | 26,7 | Coefficient of variation | 32,0 | 35,0 | 40,4 | 22,0 | 31,0 | 24,1 | Coefficient of variation | 41,7 | 34,5 | 45,8 | 36,2 | 44,4 |
| Upper confidence limit | 1,01 | 1,12 | 1,04 | 1,06 | 1,26 | 1,23 | 1,42 | 0,86 | 1,25 | 1,27 | 1,23 | 1,18 | 0,84 | 1,00 | 1,09 | Upper confidence limit | 1,15 | 1,18 | 1,42 | 0,99 | 1,11 | 1,07 | Upper confi- dence limit | 1,42 | 1,14 | 1,28 | 1,11 | 1,28 |
| Lower confi- dence limit | 0,85 | 0,92 | 0,87 | 0,91 | 1,11 | 1,05 | 1,24 | 0,67 | 1,03 | 1,12 | 1,06 | 1,02 | 0,66 | 0,83 | 0,90 | Lower confi- dence limit | 0,98 | 1,02 | 1,24 | 0,82 | 0,95 | 0,84 | Lower confidence limit | 1,24 | 0,97 | 1,10 | 0,95 | 1,13 |
| SD | 0,94 | 1,03 | 0,99 | 0,99 | 1,19 | 1,17 | 1,33 | 0,77 | 1,15 | 1,21 | 1,15 | 1,10 | 0,76 | 0,91 | 1,04 | SD | 1,07 | 1,10 | 1,32 | 0,90 | 1,03 | 0,97 | SD | 1,35 | 1,05 | 1,19 | 1,03 | 1,20 |
| Question | PHY_1_1 | PHY_1_2 | PHY_1_3 | PHY_1_4 | PHY_1_5 | PHY_1_6 | PHY_1_7 | PHY_1_9 | PHY_1_10 | PHY_1_11 | PHY_1_13 | PHY_1_16 | PHY_1_20 | PHY_1_21 | PHY_1_25 | Question | PHY_2_1 | PHY_2_2 | PHY_2_7 | PHY_2_9 | PHY_2_10 | PHY_2_12 | Question | PHY_3_3 | PHY_3_4 | PHY_3_5 | PHY_3_6 | PHY 3.8 |

| Comments | | practical insignificance | practical insignificance | practical insignificance | | practical insignificance | | duplication | duplication | | duplication of the HTN- specific part | duplication of the HTN- specific part | duplication of the HTN- specific part | | |
|-------------------------------|---------|-----------------------------|-----------------------------|-----------------------------|---------|-----------------------------|---------|-------------|-------------|----------|---|---|---|----------|----------|
| Selected | > | × | × | × | > | × | > | × | × | > | × | × | × | > | > |
| Did not meet the criteria | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Q | 0 | ო | 0 |
| Met the criteria | 8 | ω | 7 | ω | 8 | ω | 8 | 80 | 8 | 80 | ω | N | ω | 5 | 8 |
| Pearson's r | 0,80 | 0,72 | 0,70 | 0,71 | 0,76 | 0,78 | 0,85 | 0,82 | 0,82 | 0,75 | 0,84 | 0,54 | 0,81 | 0,67 | 0,71 |
| Cronbach's α | 0,74 | 0,65 | 0,62 | 0,63 | 0,68 | 0,69 | 0,80 | 0,78 | 0,75 | 0,75 | 0,80 | 0,42 | 0,73 | 0,57 | 0,61 |
| TT3_ discriminant_A | 1,24 | 1,11 | 1,00 | 0,94 | 1,07 | 1,14 | 1,79 | 1,40 | 1,64 | 1,16 | 1,85 | 0,75 | 2,00 | 1,20 | 1,16 |
| TT3_b4 | -0,88 | -0,7 | -2,19 | -1,58 | -1,44 | -1,6 | -0,05 | 0,626 | 0,05 | 0,64 | -0,17 | -3,09 | -0,8 | -1.12 | -0,7 |
| TT3_b1 | -2,9 | -2,73 | -2,47 | -2,26 | -2,28 | -2,47 | -1,93 | -2,14 | -2,2 | -2,26 | -2,41 | -4,67 | -2,3 | -2,13 | -2,66 |
| Upper confi-dence limit | 35,7 | 34,9 | 28,3 | 34,2 | 35,9 | 33,2 | 41,4 | 43,3 | 38,4 | 39,7 | 36,0 | 20,0 | 32,4 | 25,1 | 32,2 |
| Lower confi-dence limit | 30,0 | 29,0 | 22,2 | 27,2 | 28,9 | 26,5 | 34,7 | 36,8 | 32,1 | 33,4 | 30,6 | 14,8 | 25,7 | 20,0 | 25,6 |
| Coefficient of variation | 32,9 | 32,1 | 25,4 | 30,9 | 32,4 | 30,0 | 38,1 | 40,1 | 35,2 | 36,6 | 33,2 | 17,1 | 29,2 | 22,5 | 29,1 |
| Upper confi- dence limit | 1,32 | 1,26 | 1,16 | 1,32 | 1,36 | 1,29 | 1,42 | 1,39 | 1,34 | 1,28 | 1,28 | 0,83 | 1,27 | 1,05 | 1,25 |
| Lower confi-dence limit | 1,17 | 1,10 | 0,96 | 1,11 | 1,16 | 1,10 | 1,25 | 1,24 | 1,18 | 1,12 | 1,14 | 0,65 | 1,07 | 0,86 | 1,05 |
| SD | 1,25 | 1,18 | 1,07 | 1,22 | 1,26 | 1,20 | 1,33 | 1,32 | 1,26 | 1,20 | 1,22 | 0,80 | 1,17 | 0,96 | 1,16 |
| Question | PHY_4_2 | PHY_4_3 | PHY_4_4 | PHY_4_5 | PHY_4_7 | PHY_4_8 | PHY_4_9 | PHY_4_10 | PHY_4_12 | PHY_4_13 | PHY_4_14 | PHY_4_15 | PHY_4_17 | PHY_4_19 | PHY_4_20 |

| ments | | |
|-------------------------------|---------|---------|
| d Com | | |
| Selecte | × | × |
| Did not meet the criteria | 4 | 4 |
| Met the criteria | 4 | 4 |
| Pearson's r | 0,03 | 0,44 |
| Cronbach's α | 0,03 | 0,44 |
| TT3_ discriminant_A | 0,10 | 0,40 |
| ТТЗ_b4 | 6,11 | 3,5 |
| TT3_b1 | -5,46 | -2,74 |
| Upper confi-dence limit | 35,7 | 43,1 |
| Lower confi- dence limit | 28,8 | 35,9 |
| Coefficient of variation | 32,3 | 40,9 |
| Upper confi- dence limit | 1,15 | 1,10 |
| Lower confi-dence limit | 0,98 | 0,91 |
| SD | 1,10 | 1,05 |
| Question | PHY_5_1 | PHY_5_2 |

| Comments | | | | practical insignificance | practical insignificance | | practical insignificance | practical insignificance | practical insignificance | | practical insignificance | | | practical insignificance | | |
|---------------------------------|---------|---------|---------|-----------------------------|-----------------------------|---------|-----------------------------|-----------------------------|-----------------------------|----------|-----------------------------|----------|----------|-----------------------------|----------|----------|
| Selected | > | > | > | × | × | × | × | × | × | > | × | > | > | × | > | > |
| Did not meet the criteria | - | 2 | 2 | 2 | 2 | 9 | - | 5 | e | 2 | ი | 2 | + | 5 | 0 | 0 |
| Met the criteria | 7 | 9 | 9 | 9 | 9 | 2 | 7 | 9 | 2 | 9 | 2 | 9 | 7 | 9 | 8 | 8 |
| Pearson's r | 0,75 | 0,75 | 0,73 | 0,80 | 0,69 | 0,53 | 0,61 | 0,68 | 0,71 | 0,78 | 0,66 | 0,77 | 0,75 | 0,59 | 0,63 | 0,86 |
| Cronbach's α | 0,61 | 0,61 | 0,65 | 0,68 | 0,55 | 0,49 | 0,53 | 0,62 | 0,58 | 0,67 | 0,64 | 0,69 | 0,75 | 0,61 | 0,70 | 0,78 |
| TT3_ discriminant_A | 0,68 | 0,80 | 0,78 | 0,89 | 0,58 | 0,55 | 0,48 | 0,68 | 0,75 | 0,98 | 0,96 | 0,99 | 1,21 | 0,76 | 0,92 | 1,36 |
| TT3_b4 | 1,68 | -0,76 | 0,17 | 0,95 | -1,94 | -2,69 | -0,12 | 1,84 | -1,77 | 0,05 | 0,77 | 0,58 | 0,40 | -0,49 | 0,32 | 0,19 |
| TT3_b1 | -3,10 | -3,87 | -4,48 | -3,48 | -6,30 | -4,49 | -1,26 | -3,97 | -2,90 | -4,14 | -3,08 | -3,07 | -3,84 | -3,53 | -2,31 | -2,66 |
| Upper confi- dence limit | 37,8 | 27,4 | 30,7 | 32,0 | 28,1 | 22,7 | 38,8 | 33,6 | 25,9 | 30,4 | 28,0 | 31,2 | 31,7 | 30,4 | 39,1 | 34,1 |
| Lower confi- dence limit | 31,1 | 21,2 | 24,1 | 25,3 | 21,4 | 16,5 | 28,9 | 27,6 | 19,0 | 23,6 | 21,5 | 24,1 | 25,6 | 23,9 | 31,3 | 26,7 |
| Coefficient of variation | 34,5 | 24,4 | 27,5 | 28,7 | 24,9 | 19,8 | 34,0 | 30,7 | 22,5 | 27,1 | 24,8 | 27,7 | 28,7 | 27,2 | 35,2 | 30,5 |
| Upper confi- dence limit | 1,21 | 1,11 | 1,16 | 1,19 | 1,15 | 0,98 | 1,45 | 1,15 | 1,08 | 1,17 | 1,05 | 1,15 | 1,17 | 1,18 | 1,35 | 1,26 |
| Lower confi- dence limit | 1,03 | 0,91 | 0,97 | 0,99 | 0,92 | 0,75 | 1,18 | 0,98 | 0,84 | 0,96 | 0,84 | 0,94 | 1,00 | 0,99 | 1,15 | 1,05 |
| SD | 1,12 | 1,02 | 1,07 | 1,09 | 1,04 | 0,88 | 1,32 | 1,06 | 0,97 | 1,07 | 0,95 | 1,05 | 1,09 | 1,09 | 1,26 | 1,16 |
| Question | PSY_1_1 | PSY_1_2 | PSY_1_3 | PSY_1_5 | PSY_1_6 | PSY_1_8 | PSY_1_13 | PSY_1_14 | PSY_1_20 | PSY_1_23 | PSY_1_24 | PSY_1_25 | PSY_1_28 | PSY_1_29 | PSY_1_30 | PSY_1_33 |

| Ouestion | | lower confi- | I Inner confi- | Coefficient | lower confi- | I Inner confi- | TT3 h1 | TT3 h4 | 113 | Cronhach's or | Daareon'e r | Mat the | Did not | Salantard | Commante |
|----------|------|--------------|----------------|--------------|--------------|----------------|--------|--------|----------------|---------------|-------------|----------|----------|-----------|----------------|
| | 5 | dence limit | dence limit | of variation | dence limit | dence limit | | 5 | discriminant A | 2000 | | criteria | meet the | 2000 | |
| | | | | | | | | | I | | | | criteria | | |
| PSY_2_1 | 1,08 | 0,99 | 1,17 | 31,6 | 28,2 | 34,9 | -3,10 | 1,85 | 0,95 | 0,66 | 0,85 | 9 | 2 | > | |
| PSY_2_2 | 1,13 | 1,05 | 1,21 | 32,4 | 29,4 | 35,3 | -3,48 | 0,43 | 1,01 | 0,70 | 0,88 | 7 | - | > | |
| PSY_2_5 | 1,04 | 0,95 | 1,13 | 28,3 | 25,0 | 31,5 | -2,99 | 0,65 | 1,44 | 0,76 | 0,89 | 7 | - | > | |
| PSY_2_7 | 1,13 | 1,04 | 1,21 | 30,8 | 27,7 | 33,8 | -3,31 | 0,33 | 1,52 | 0,78 | 0,87 | 7 | - | > | |
| PSY_2_12 | 0,99 | 0,90 | 1,08 | 24,7 | 21,7 | 25,7 | -3,45 | -0,04 | 1,32 | 0,71 | 0,80 | 5 | S | × | practical |
| | | | | | | | | | | | | | | | insignificance |

| Question | SD | Lower confidence limit | Upper confidence limit | Coefficient of variation | Lower confi- dence limit | Upper confi- dence limit | TT3_b1 | TT3_b4 | TT3_ discriminant_A | Cronbach's α | Pearson's r | Met the criteria | Did not meet the criteria | Selected | Comments |
|----------|------|------------------------|--------------------------------|--------------------------|-----------------------------|---------------------------------|---------|---------|-------------------------|---------------------|--------------|-----------------------|---------------------------------|----------|-----------------------------|
| PSY_4_2 | 1,09 | 1,01 | 1,17 | 31,8 | 28,8 | 34,7 | -2,90 | 1,42 | 1,33 | 0,74 | 0,81 | ω | 0 | > | |
| PSY_4_3 | 1,01 | 0,93 | 1,09 | 26,5 | 23,8 | 29,1 | -4,11 | 0,28 | 1,54 | 0,72 | 0,78 | 9 | 2 | × | practical insignificance |
| PSY_4_5 | 1,10 | 1,01 | 1,19 | 32,8 | 29,7 | 36,0 | -2,59 | 1,53 | 1,51 | 0,74 | 0,79 | 8 | 0 | > | |
| PSY_4_6 | 1,02 | 0,92 | 1,11 | 26,1 | 23,0 | 29,0 | -3,53 | 0,26 | 1,33 | 0,71 | 0,80 | 9 | 2 | × | practical insignificance |
| PSY_4_7 | 1,08 | 1,00 | 1,15 | 29,2 | 26,4 | 32,0 | -3,64 | 0,58 | 1,44 | 0,76 | 0,85 | 7 | - | × | practical insignificance |
| PSY_4_8 | 1,01 | 0,92 | 1,09 | 25,6 | 22,8 | 28,2 | -4,08 | 0,10 | 1,48 | 0,72 | 0,81 | 9 | 2 | > | |
| PSY_4_9 | 1,08 | 1,00 | 1,16 | 30,9 | 28,1 | 33,6 | -3,33 | 1,21 | 1,56 | 0,75 | 0,80 | 7 | - | > | |
| PSY_4_10 | 0,96 | 0,88 | 1,04 | 23,9 | 21,3 | 26,3 | -2,12 | 0,61 | 1,21 | 0,70 | 0,77 | 9 | 5 | × | practical insignificance |
| PSY_4_11 | 1,07 | 0,96 | 1,17 | 26,9 | 23,3 | 30,3 | -3,17 | 0,03 | 1,19 | 0,68 | 0,78 | 9 | 2 | > | |
| PSY_4_13 | 0,96 | 0,86 | 1,05 | 22,9 | 19,9 | 25,6 | -4,98 | -0,67 | 0,81 | 0,58 | 0,71 | 4 | 4 | × | |
| PSY_4_14 | 1,04 | 0,93 | 1,14 | 25,6 | 22,2 | 28,9 | -4,03 | 0,42 | 0,78 | 0,59 | 0,77 | 9 | 2 | > | |
| PSY_4_18 | 0,99 | 0,89 | 1,09 | 22,4 | 21,1 | 27,2 | -3,50 | -0,27 | 1,82 | 0,76 | 0,83 | 5 | 3 | × | |
| PSY_4_21 | 0,91 | 0,81 | 1,01 | 21,5 | 18,5 | 24,3 | -3,44 | -0,26 | 1,58 | 0,73 | 0,81 | 4 | 4 | × | |
| | | | | | | | | | | | | | | | |
| Question | SD | Lower confi- | Upper | Coefficient | ower confi- | Upper | TT3_b1 | TT3_b4 | TT3_ | Cronbach's | Pearson's r | Aet the | Did not | Selected | Comments |
| | | dence limit | confi- dence limit | of variation | dence limit | confidence limit | | | discriminant_A | α | 0 | criteria | meet the criteria | | |
| PSY_5_4 | 0,94 | 0,85 | 1,03 | 34,3 | 30,8 | 37,8 | -5,59 | 3,82 | 0,33 | 0,34 | 0,92 | ~ | 5 | × | |
| PSY_5_5 | 0,95 | 0,85 | 1,04 | 33,1 | 29,6 | 36,7 | - 5,88 | 3,83 | 0,31 | 0,35 | 0,93 | ~ | IJ | > | practical significance |
| PSY_5_6 | 0,84 | 0,74 | 0,94 | 30,6 | 27,0 | 34,1 | -4,96 | 1,84 | 0,50 | 0,46 | 0,87 2 | | 4 | > | practical significance |
| | | | | | | | | | | | | | | | 0 |
| Question | SD | Lower confidence limit | Upper confi- dence limit | Coefficient of variation | Lower conf dence limit | i- Upper confidence limit | a TT3 b | 1 TT3_b | 4 TT3_ discriminant_ | Cronbach A α | 's Pearson's | r Met the criteria | Did not meet the criteria | Selected | Comments |
| SOC_1_1 | 1,17 | 1,09 | 1,25 | 39,5 | 35,9 | 43,1 | -3, 15 | 5,43 | 0,30 | 0,40 | 0,68 | ო | 5 | > | practical significance |
| SOC_1_2 | 0,85 | 0,75 | 0,95 | 20,4 | 17,5 | 23,1 | -0,80 | 0,34 | 0,86 | 0,52 | 0,63 | 4 | 4 | × | |
| SOC_1_7 | 1,08 | 0,98 | 1,17 | 29,2 | 25,7 | 32,6 | -3,04 | 1,73 | 0,75 | 0,60 | 0,72 | 9 | 5 | × | practical insignificance |
| SOC_1_8 | 1,14 | 1,06 | 1,23 | 33,8 | 30,3 | 37,2 | -2,30 | 1,91 | 0,82 | 0,65 | 0,81 | œ | 0 | > | |

| nts | | | | | nts | | | | | | ts | on FN- aart | on FN- bart | nts | | ion TN- part | ion TN- part | ıts | nce | | | |
|---------------------------------|---------|---------|---------|---------|-----------------------------|---------|---------|---------|---------|---------|---------------------------------|--------------------------------------|--------------------------------------|---------------------------------|----------|--|--|---------------------------------|-------------------------|----------|----------|----------|
| Commer | | | | | Commer | | | | | | Commer | duplicati of the HT specific p | duplicati of the HT specific p | Commer | | duplicati of the H ^T specific | duplicati of the H ⁻ specific | Commer | practical significal | | | |
| Selected | × | > | > | > | Selected | × | > | × | × | × | Selected | × | × | Selected | > | × | × | Selected | > | > | > | × |
| Did not meet the criteria | 9 | e | ო | ო | Did not meet the | 5 | | 5 | 4 | 9 | Did not meet the criteria | ю | N | Did not meet the criteria | e | е | 4 | Did not meet the criteria | 4 | 03 | - | 9 |
| Met the criteria | 2 | 5 | ß | ъ 2 | Met the criteria | e | 7 | ი | 4 | 2 | Met the criteria | ى ك | Q | Met the criteria | 5 | Q | 4 | Met the criteria | 4 | 5 | 7 | 2 |
| Pearson's r | 0,67 | 0,76 | 0,75 | 0,76 | Pearson's r | 0,66 | 0,71 | 0,65 | 0,62 | 0,50 | Pearson's r | 0,96 | 0,96 | Pearson's r | 0,82 | 0,85 | 0,82 | Pearson's r | 0,70 | 0,65 | 0,63 | 0,56 |
| Cronbach's α | 0,43 | 0,60 | 0,58 | 0,56 | Cronbach's α | 0,53 | 0,57 | 0,42 | 0,50 | 0,42 | Cronbach's α | 0,51 | 0,55 | Cronbach's α | 0,57 | 0,57 | 0,61 | Cronbach's α | 0,47 | 0,52 | 0,54 | 0,35 |
| TT3_ discriminant_A | 0,83 | 1,08 | 1,08 | 1,19 | TT3_ discriminant_A | 0,89 | 0,74 | 0,60 | 0,80 | 0,49 | TT3_ discriminant_A | 0,52 | 0,65 | TT3discriminant_A | 1,7 | 1,5 | 2,3 | П3_ discriminant_A | 0,80 | 1,13 | 0,74 | 0,45 |
| TT3_b4 | 0,35 | 0,42 | 1,27 | 0,08 | TT3_b4 | 1,07 | 1,33 | 1,72 | 0,25 | -0,05 | TT3_b4 | 0,27 | 0,26 | TT3_b4 | 0,5 | 0,9 | 0'0 | TT3_b4 - | 1,80 (| 1,43 | 1,50 (| 3,10 (|
| TT3_b1 | -3,69 | -1,92 | -3,75 | -1,10 | ПЗ_b1 | -4,00 | -2,75 | -3,31 | -2,67 | -3,80 | TT3_b1 | -6,43 | -2,12 | П3_b1 | -2,1 | -2,8 | -2,0 | ПЗ_b1 | -3,10 | -1,10 | -3,90 | -2,45 |
| Upper confidence limit | 20,6 | 24,2 | 25,7 | 23,9 | Upper confi- dence limit | 23,5 | 31,3 | 24,9 | 22,1 | 27,3 | Upper confi- dence limit | 28,3 | 27,0 | Upper confi- dence limit | 23 | 22 | 19 | Jpper confi- dence limit | 58 | 24 | 50 | 30,1 |
| Lower confi- dence limit | 14,7 | 19,4 | 20,8 | 18,3 | Lower confi- dence limit | 18,2 | 24,6 | 19,7 | 16,1 | 20,0 | Lower confi- dence limit | 23,6 | 22,4 | Lower confi- dence limit | 16 | 17 | 14 | -ower confi- dence limit | 1 | 17 | 22 | 19,3 |
| Coefficient of variation | 17,6 | 21,9 | 23,3 | 21,2 | Coefficient of variation | 20,9 | 28,0 | 22,4 | 19,2 | 23,8 | Coefficient of variation | 26,0 | 24,9 | Coefficient of variation | 20 | 20 | 16 | Coefficient of 1 variation 0 | 25 | 21 | 25 | 25,1 |
| Upper confi- dence limit | 0,88 | 0,98 | 0,97 | 0,99 | Upper confi- | 0,94 | 1,16 | 0,96 | 0,92 | 1,11 | Upper confidence limit | 1,07 | 1,04 | Upper confi- dence limit | 0,92 | 0,85 | 0,80 | Upper confi- dence limit | 0,99 | 0,91 | 1,04 | 0,90 |
| Lower confi- dence limit | 0,65 | 0,82 | 0,82 | 0,79 | Lower confi- dence limit | 0,76 | 0,96 | 0,78 | 0,70 | 0,86 | Lower confi- dence limit | 0,92 | 0,90 | Lower confi- dence limit | 0,67 | 0,68 | 0,61 | Lower confi- dence limit | 0,78 | 0,68 | 0,82 | 0,59 |
| SD | 0,77 | 0,91 | 0,90 | 0,90 | SD | 0,85 | 1,06 | 0,87 | 0,82 | 0,99 | SD | 0,99 | 0,98 | SD | 0,77 | 0,72 | 0,58 | SD | 0,88 | 0,78 | 1,01 | 0,78 |
| Question | SOC_2_1 | SOC_2_3 | SOC_2_5 | SOC_2_8 | Question | SOC 3_1 | SOC_3_3 | SOC_3_4 | SOC_3_5 | SOC_3_7 | Question | SOC_4_1 | SOC_4_2 | Question | THER_1_1 | THER_1_2 | THER_1_3 | Question | THER_2_1 | THER_2_2 | THER_2_3 | THER_2_7 |

| Comments | practical significance | | practical significance | Comments | | practical significance | practical significance | practical insignificance | | | Comments | | | | | practical significance | | | Comments | | | | | oractical nsignificance |
|---------------------------------|---------------------------|----------|---------------------------|-----------------------------------|----------|---------------------------|---------------------------|-----------------------------|----------|----------|-----------------------------------|----------|----------|----------|----------|---------------------------|----------|----------|----------------|--------------------------|----------|----------|----------|----------------------------|
| Selected | > | × | × | Selected | > | > | > | × | > | > | Selected | × | × | × | × | > | × | × | Selected (| | × | > | > | × |
| Did not meet the criteria | 4 | 7 | Ŋ | Did not meet the criteria | ŝ | 4 | 4 | 7 | ю | co | Did not meet the criteria | 7 | 7 | 7 | 5 | 4 | 80 | 7 | Did not | meet the criteria | 8 | 2 | с | ო |
| Met the criteria | 4 | - | ი | criteria | 5 | 4 | 4 | 9 | £ | 5 | Met the criteria | - | - | - | ო | 4 | 0 | - | Met the | criteria | 0 | 6 | 5 | 5 |
| Pearson's r | 0,82 | 0,76 | 0,84 | Pearson's r | 0,61 | 0,67 | 0,66 | 0,60 | 0,62 | 0,55 | Pearson's r | 0,58 | 0,46 | 0,52 | 0,65 | 0,57 | 0,42 | 0,59 | Pearson's r | | 0,34 | 0,78 | 0,80 | 0,57 |
| Cronbach's α | 0,51 | 0,33 | 0,41 | Cronbach's α | 0,58 | 0,67 | 0,69 | 0,57 | 0,51 | 0,47 | Cronbach's α | 0,37 | 0,33 | 0,34 | 0,43 | 0,54 | 0,32 | 0,33 | Cronbach's | ರ | 0,29 | 0,53 | 0,50 | 0,22 |
| TT3_ discriminant_A | 1,35 | 0,48 | 0,81 | TT3_ discriminant_A | 1,12 | 1,89 | 1,81 | 0,62 | 0,72 | 0,54 | TT3_ discriminant_A | 0,45 | 0,29 | 0,35 | 0,47 | 0,92 | 0,35 | 0,16 | 113 | discriminant_A | 0,31 | 0,39 | 0,39 | 0,14 |
| TT3_b4 | 2,60 | 4,80 | 3,08 | TT3_b4 | 0,57 | 0,87 | -0,04 | 0,73 | -0,50 | -0,27 | TT3_b4 | 1,45 | 3,37 | 0,34 | -0,05 | -0,98 | -0,23 | -5,27 | TT3 b4 | I | -1,17 | 1,65 | 2,85 | 0,23 |
| П3_b1 | -2,60 | -5,00 | -0,67 | TT3_b1 | -2,14 | -2,11 | -2,35 | -4,80 | - 1,64 | -4,76 | TT3_b1 | -4,60 | -5,67 | -4,65 | -1,60 | -2,08 | -6,90 | -8,30 | TT3 b1 | I | -6,70 | -6,26 | -5,55 | -4,47 |
| Upper confi- dence limit | 21,4 | 22,1 | 25,6 | Upper confi- dence limit | 25,3 | 20,8 | 22,6 | 34 | 26,4 | 30,8 | Upper confi- dence limit | 17,3 | 23 | 22 | 28 | 18 | 21 | 23,3 | Upper confi- | dence limit | 18,4 | 38,8 | 36,3 | 36,3 |
| Lower confi- dence limit | 16,7 | 16,0 | 18,3 | Lower confi- dence limit | 19,5 | 15,3 | 14,7 | 26 | 19,9 | 22,8 | Lower confidence limit | 12,6 | 16 | 14 | 18 | 12 | 14 | 14,2 | Lower confi- | dence limit | 13,2 | 30,6 | 27,4 | 25,2 |
| Coefficient of variation | 19,1 | 19,1 | 22,2 | Coefficient of variation | 22,3 | 18,2 | 18,8 | 30 | 23,3 | 27,0 | Coefficient of variation | 15,0 | 20 | 19 | 23 | 15 | 17 | 19,1 | Coefficient of | variation | 16,1 | 34,7 | 31,9 | 31,1 |
| Upper confi- dence limit | 0,74 | 0,70 | 0,86 | Upper confi- dence limit | 0,98 | 0,83 | 0,93 | 1,20 | 1,05 | 1,17 | Upper confi- dence limit | 0,72 | 0,91 | 0,93 | 1,11 | 0,81 | 0,90 | 1,02 | Upper | confi- dence limit | 0,80 | 1,28 | 1,21 | 1,33 |
| Lower confidence limit | 0,56 | 0,49 | 0,63 | Lower confidence limit | 0,79 | 0,63 | 0,63 | 0,97 | 0,84 | 0,93 | Lower confidence limit | 0,54 | 0,64 | 0,63 | 0,76 | 0,55 | 0,63 | 0,66 | Lower | confidence limit | 0,60 | 1,07 | 0,97 | 1,01 |
| SD | 0,65 | 0,65 | 0,70 | SD | 0,89 | 0,73 | 0,79 | 1,09 | 0,95 | 1,06 | S | 0,63 | 0,78 | 0,79 | 0,95 | 0,70 | 0,77 | 0,85 | SD | | 0,71 | 1,17 | 1,09 | 1,19 |
| Question | THER_3_1 | THER_3_2 | THER_3_4 | Question | THER_5_1 | THER_5_2 | THER_5_3 | THER_5_5 | THER_5_6 | THER_5_7 | Question | THER_6_1 | THER_6_2 | THER_6_3 | THER_6_4 | THER_6_6 | THER_6_7 | THER_6_8 | Question | | THER_7_1 | THER_7_2 | THER_7_3 | THER_7_5 |

| cted Comments | practical significance | practical significance | practical significance | | practical insignificance | | | practical significance | | | practical significance | | |
|--------------------------------|---------------------------|---------------------------|---------------------------|---------------|-----------------------------|-----------|---------------|---------------------------|---------------|----------------|---------------------------|----------------|----------------|
| t Selec he | > | > | > | > | × | × | > | > | > | > | > | × | × |
| Did no meet t criteria | Q | വ | Q | 2 | 4 | 7 | ო | 4 | 2 | 0 | 4 | Q | 9 |
| . Met the criteria | ო | ო | ო | 9 | 4 | - | ъ | 4 | 9 | œ | 4 | ო | 0 |
| Pearson's r | 0,41 | 0,44 | 0,30 | 0,55 | 0,30 | 0,44 | 0,57 | 0,62 | 0,61 | 0,67 | 0,50 | 0,41 | 0,35 |
| Cronbach's α | 0,15 | 0,21 | 0,06 | 0,40 | 0,32 | 0,20 | 0,44 | 0,46 | 0,47 | 0,51 | 0,37 | 0,30 | 0,29 |
| TT3_ discriminant_A | 0,25 | 0,27 | 0,24 | 0,63 | 0,39 | 0,46 | 1,01 | 0,93 | 0,85 | 1,30 | 0,89 | 0,33 | 0,36 |
| TT3_b4 | 1,50 | 1,40 | 1,50 | 1,00 | 0,72 | 0,72 | 0,09 | 0,30 | 0,43 | 1,30 | 3,20 | 0,70 | 1,14 |
| TT3_b1 | -6,00 | -6,50 | -8,30 | -3,80 | -4,50 | 0,90 | -2,23 | -3,00 | -2,86 | -1,10 | 0,56 | -1,90 | -4,60 |
| Upper confidence limit | 29,5 | 30,0 | 30,1 | 34,3 | 36,0 | 17,1 | 26,6 | 26,8 | 31,2 | 37,8 | 42,7 | 26,3 | 26,2 |
| Lower confidence limit | 24,8 | 25,6 | 25,7 | 29,2 | 29,1 | 12,3 | 21,4 | 22,3 | 25,0 | 32,0 | 36,2 | 21,1 | 22,6 |
| Coefficient of variation | 27,2 | 27,8 | 27,9 | 31,8 | 32,6 | 14,8 | 24,1 | 24,5 | 28,2 | 34,9 | 39,4 | 23,7 | 24,4 |
| Upper confi- dence limit | 1,08 | 1,08 | 1,10 | 1,20 | 1,30 | 0,77 | 1,08 | 1,05 | 1,20 | 1,16 | 1,13 | 1,03 | 0,97 |
| Lower confi- dence limit | 0,94 | 0,95 | 0,97 | 1,06 | 1,11 | 0,57 | 0,91 | 0,91 | 0,98 | 1,01 | 0,99 | 0,85 | 0,85 |
| SD | 1,01 | 1,02 | 1,04 | 1,13 | 1,21 | 0,68 | 0,99 | 0,98 | 1,10 | 1,09 | 1,06 | 0,94 | 0,91 |
| Question | HTN_ PHY_1 | HTN_ PHY_2 | HTN_ PHY_3 | HTN_ PHY_4 | HTN_PHY_5 | HTN_PHY_6 | HTN_ PHY_7 | HTN_ PHY_8 | HTN_ PHY_9 | HTN_ PHY_10 | HTN_ PHY_12 | HTN_ PHY_13 | HTN_ PHY_14 |

| d Comments | practical significance | practical insignificance | | |
|---------------------------------|---------------------------|-----------------------------|---------------|---------------|
| Selected | > | × | > | > |
| Did not meet the criteria | 4 | 9 | - | - |
| Met the criteria | 4 | 5 | 2 | 7 |
| Pearson's r | 0,44 | 0,74 | 0,82 | 0,43 |
| Cronbach's α | 0,20 | 0,20 | 0,38 | 0,50 |
| TT3_ discriminant_A | 0,16 | 0,08 | 0,67 | 0,54 |
| TT3_b4 | -1,70 | 2,80 | 1,75 | 1,12 |
| TT3_b1 | -4,50 | -2,52 | -0,63 | -1,49 |
| Upper confi- dence limit | 32,5 | 45,9 | 48,4 | 46,9 |
| Lower confi- dence limit | 27,0 | 39,1 | 41,8 | 40,5 |
| Coefficient of variation | 29,8 | 42,5 | 45,1 | 43,6 |
| Upper confi- dence limit | 1,21 | 1,49 | 1,39 | 1,42 |
| Lower confi- dence limit | 1,05 | 1,35 | 1,25 | 1,29 |
| SD | 1,14 | 1,42 | 1,32 | 1,35 |
| Question | HTN_ PSY_1 | HTN_PSY_2 | HTN_ PSY_3 | HTN_ PSY_4 |

| omments | | | actical jnificance | actical significance | | | omments | actical jnificance | actical jnificance | actical Jnificance | actical inificance | actical jnificance | actical significance | | actical significance | actical significance | actical significance | actical significance | | |
|---------------------------------|-----------|-----------|-----------------------|-------------------------|-----------|---------------|-----------------------------------|------------------------|-----------------------|------------------------------------|-----------------------|------------------------|-------------------------|----------------|-------------------------|-------------------------|-------------------------|-------------------------|-----------------|----------------|
| Selected Co | × | × | ∕ Si | × | > | > | Selected Co | <pre>> pr sig</pre> | × sić | pr si | × siç | <pre>> pr sig</pre> | * | × | × | * | * | × × | × | × |
| Did not meet the criteria | 5 | 5 | 2 | ო | 0 | 0 | Did not meet the criteria | Ð | 9 | 5 | 4 | 4 | 4 | 9 | 4 | ი | ო | 4 | 5 | ω |
| Met the criteria | e | e | e | ى ک | 8 | 9 | Met the criteria | ო | N | ი | 4 | 4 | 4 | N | 4 | 2 | ъ | 4 | ო | 0 |
| Pearson's r | 0,54 | 0,68 | 0,55 | 0,43 | 0,66 | 0,68 | Pearson's r | 0,52 | 0,65 | 0,57 | 0,71 | 0,65 | 0,35 | 0,43 | 0,24 | 0,30 | 0,29 | 0,48 | 0,45 | 0,12 |
| Cronbach's α | 0,49 | 0,44 | 0,36 | 0,17 | 0,50 | 0,52 | Cronbach's α | 0,43 | 0,14 | 0,24 | 0,24 | 0,33 | 0,34 | 0,39 | 0,10 | 0,03 | 0,22 | 0,35 | 0,13 | 0,03 |
| TT3_ discriminant_A | 0,43 | 0,37 | 0,37 | 0,20 | 2,58 | 2,99 | TT3_ discriminant_A | 0,48 | 0,18 | 0,29 | 0,19 | 0,23 | 0,31 | 0,46 | 0,17 | 0,12 | 0,17 | 0,28 | 0,19 | 0,25 |
| TT3_b4 | 1,98 | 1,64 | 1,40 | 0,88 | 0,57 | 1,06 | TT3_b4 | 2,08 | 0,08 | 2,59 | 3,66 | -0,40 | -0,84 | 0,64 | 2,66 | 2,80 | -0,87 | 4,80 | 1,64 | 2,20 |
| ТТ3_b1 | -4,30 | -3,38 | -4,14 | -3,30 | -1,36 | -1,29 | TT3_b1 | -3,34 | -4,14 | -3,04 | -1,55 | -3,46 | -4,97 | -5,85 | -3,30 | 2,40 | -2,82 | -5,40 | -5,37 | -5,80 |
| Upper confi- dence limit | 27,6 | 28,5 | 25,0 | 38,7 | 32,3 | 32,6 | Upper confidence limit | 23,8 | 24,2 | 24,5 | 27,9 | 27,6 | 30,2 | 26,2 | 36,7 | 62,6 | 30,5 | 36,9 | 29,1 | 18,2 |
| Lower confidence limit | 22,4 | 23,5 | 20,0 | 31,9 | 27,0 | 27,4 | Lower confi- dence limit | 20,0 | 18,7 | 20,2 | 21,3 | 21,9 | 24,3 | 21,7 | 29,8 | 56,0 | 24,0 | 31,9 | 23,8 | 14,6 |
| Coefficient of variation | 25,1 | 26,1 | 22,6 | 35,3 | 29,7 | 30,0 | Coefficient of variation | 21,9 | 21,5 | 22,3 | 24,7 | 24,9 | 27,4 | 24,0 | 33,4 | 59,2 | 27,3 | 34,4 | 26,5 | 16,4 |
| Upper confidence limit | 1,06 | 1,04 | 0,98 | 1,38 | 1,18 | 1,11 | Upper confi- dence limit | 0,89 | 0,99 | 0,92 | 1,15 | 1,10 | 1,19 | 1,03 | 1,31 | 1,34 | 1,19 | 1,23 | 1,10 | 0,80 |
| Lower confi- dence limit | 0,89 | 0,89 | 0,81 | 1,21 | 1,03 | 0,96 | Lower confi- dence limit | 0,76 | 0,79 | 0,77 | 0,92 | 0,91 | 1,01 | 0,88 | 1,13 | 1,14 | 0,99 | 1,09 | 0,93 | 0,66 |
| SD | 0,97 | 0,97 | 0,90 | 1,30 | 1,11 | 1,03 | SD | 0,82 | 0,90 | 0,85 | 1,05 | 1,01 | 1,11 | 0,96 | 1,23 | 1,25 | 1,09 | 1,16 | 1,02 | 0,73 |
| Question | HTN_SOC_1 | HTN_SOC_2 | HTN_ SOC_3 | HTN_SOC_4 | HTN_SOC_5 | HTN_ SOC_7 | Question | HTN_ THER_1 | HTN_ THER_2 | HTN_ THER_3 | HTN_ THER_4 | HTN_ THER_5 | HTN_ THER_6 | HTN_ THER_7 | HTN_ THER_9 | HTN_ THER_10 | HTN_ THER_11 | HTN_ THER_12 | HTN_ THER_13 | HTN THEP 11 |

Health-related Quality-of-Life Questionnaire for Patients with Hypertension

Please answer questions regarding your general state, mood and treatment. Your answers will help your doctor work to improve the quality of care. Answer each question by marking the answer you have chosen as stated. If you are not sure how to answer the question, please choose the answer that most accurately reflects your view.

COMBINED_PHY

| How often OVE | How often OVER THE LAST 4 WEEKS have you noticed the following disorders? | | | | | | | | | |
|---------------|---|---------------|---------------------------------------|-----------------------------------|--------------------------|--------------|--|--|--|--|
| | | 5 | 4 | 3 | 2 | 1 | | | | |
| HTN_PHY_1 | Ripple in the head | Never | Rarely | At times | Often | Permanently | | | | |
| HTN_PHY_2 | Dull pressing or aching pain in the back or other part of the head | Never | Rarely | At times | Often | Permanently | | | | |
| HTN_PHY_3 | Rush of blood, fever sensation | Never | Rarely | At times | Often | Permanently | | | | |
| HTN_PHY_4 | Muscae volitantes, visual snow | Never | Rarely | At times | Often | Permanently | | | | |
| HTN_PHY_7 | Nausea with pressure increase | Never | Rarely | At times | Often | Permanently | | | | |
| HTN_PHY_8 | Feeling of pressure on the head | Never | Rarely | At times | Often | Permanently | | | | |
| HTN_PHY_9 | Trembling in the arms and/or legs | Never | Rarely | At times | Often | Permanently | | | | |
| HTN_PHY_10 | How worried were you of the symptoms of high blood pressure? | Did not worry | A bit | Moderately | Highly | Very worried | | | | |
| HTN_PHY_12 | How often have you noticed high blood pressure? | Never | Very rarely (1-2 times a month) | At times (1-2 times a week) | More than 3 times a week | Every day | | | | |
| PHY 1_2 | Vertigo | Never | Rarely | At times | Often | Permanently | | | | |
| | 1 | | | | 1 | 1 | | | | |
| PHY 1_4 | Ttightness in the chest | Never | Rarely | At times | Often | Permanently | | | | |
| PHY 1_6 | Numbness in limbs | Never | Rarely | At times | Often | Permanently | | | | |
| PHY 1_10 | Swelling of the legs | Never | Rarely | At times | Often | Permanently | | | | |

| FIII I_0 | 1401101633 11111103 | INCVCI | naiciy | At times | Olien | Fernanentiy |
|----------|--|--------|--------|----------|-------|-------------|
| PHY 1_10 | Swelling of the legs | Never | Rarely | At times | Often | Permanently |
| PHY 1_11 | Frequent night urination | Never | Rarely | At times | Often | Permanently |
| PHY 1_13 | Increased sweating | Never | Rarely | At times | Often | Permanently |
| PHY 1_16 | Sudden turbidity, blurriness, grey-out | Never | Rarely | At times | Often | Permanently |

| How often OVER THE LAST 4 WEEKS have you noted the following disorders? | | | | | | | | | |
|---|---------------------------|-------|--------|----------|-------|-------------|--|--|--|
| | | 5 | 4 | 3 | 2 | 1 | | | |
| PHY 2_1 | Poor general state | Never | Rarely | At times | Often | Permanently | | | |
| PHY 2_2 | Weakness, lethargy | Never | Rarely | At times | Often | Permanently | | | |
| PHY 2_7 | Frequent night awakenings | Never | Rarely | At times | Often | Permanently | | | |

Annex 1

| Please answ | Please answer the following questions about your health status now. | | | | | | | | |
|--------------|---|--------------------|------------------------|-----------------------|---------------------|---------------|--|--|--|
| | | 5 | 4 | 3 | 2 | 1 | | | |
| PHY 3_3 | Do you feel anxiety or depression because of your health? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes | | | |
| | | 1 | 2 | 3 | 4 | 5 | | | |
| PHY 3_5 | Are you satisfied with your physical condition, performance? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes | | | |
| PHY 3_8 | Do you feel healthy? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes | | | |
| To what exte | ent has your physical and general state lir | nited you in the f | ollowing activitie | es <u>OVER THE LA</u> | <u>ST 4 WEEKS</u> ? | | | | |
| | | 5 | 4 | 3 | 2 | 1 | | | |
| PHY 4_2 | Lift and/or carry a bag of groceries, weights | Not at al | A bit | Moderately | Rather | Extremely | | | |
| PHY 4_7 | Walk a few blocks | Not at al | A bit | Moderately | Rather | Extremely | | | |
| Did your phy | vsical condition affect your daily activities | IN THE LAST 4 | <u>NEEKS</u> in such a | way that: | | | | | |
| | | 5 | 4 | 3 | 2 | 1 | | | |
| PHY 4_9 | I had to reduce the amount of time spent on work or other matters | Never | Rarely | At times | Often | Permanently | | | |
| PHY 4_13 | Doing work required extra effort or extra time | Never | Rarely | At times | Often | Permanently | | | |
| OVER THE L | AST 4 WEEKS, to what extent did your ph | nysical condition | limit you in the fo | ollowing activitie | s: | | | | |
| | | 5 | 4 | 3 | 2 | 1 | | | |
| PHY 4_19 | In your favorite activities | Not at al | A bit | Moderately | Rather | Extremely | | | |
| PHY 4_20 | In intimate life | Not at al | A bit | Moderately | Rather | Extremely | | | |

COMBINED_PSY

| How often OVER THE LAST 4 WEEKS have you noted the following emotional states? | | | | | | | | | | |
|--|--|-------|--------|----------|-------|-------------|--|--|--|--|
| | | 5 | 4 | 3 | 2 | 1 | | | | |
| PSY 1_1 | Anxiety, emotional stress | Never | Rarely | At times | Often | Permanently | | | | |
| PSY 1_2 | Sudden and baseless scare | Never | Rarely | At times | Often | Permanently | | | | |
| PSY 1_3 | Tearfulness , low mood | Never | Rarely | At times | Often | Permanently | | | | |
| PSY 1_23 | Frequent and baseless change in sentiment | Never | Rarely | At times | Often | Permanently | | | | |
| PSY 1_25 | Constant anxiety | Never | Rarely | At times | Often | Permanently | | | | |
| PSY 1_28 | Loss of pleasure from what used to afford it | Never | Rarely | At times | Often | Permanently | | | | |
| PSY 1_30 | Feeling that you do everything very slowly | Never | Rarely | At times | Often | Permanently | | | | |
| PSY 1_33 | Feeling of burnout | Never | Rarely | At times | Often | Permanently | | | | |

| How often OVER THE LAST 4 WEEKS have you noted the following manifestations? | | | | | | | | | |
|--|--|--------------------|---------------------|---------------|--------------|---------------|--|--|--|
| | | 5 | 4 | 3 | 2 | 1 | | | |
| PSY 2_1 | Forgetfulness | Never | Rarely | At times | Often | Permanently | | | |
| PSY 2_2 | Difficulties remembering a new | Never | Rarely | At times | Often | Permanently | | | |
| PSY 2_5 | Distraction, difficulty in focusing | Never | Rarely | At times | Often | Permanently | | | |
| PSY 2_7 | Feeling that you began to think slower | Never | Rarely | At times | Often | Permanently | | | |
| Please answ | ver the following questions about how you | u satisfy with you | irself and life nov | V. | | | | | |
| | | 1 | 2 | 3 | 4 | 5 | | | |
| PSY 3_2 | Do you feel that your life is meaningful? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes | | | |
| PSY 3_9 | Do you feel that you are managing the events of your own life? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes | | | |

| OVER THE LAST 4 WEEKS, how often your emotional state influenced your daily activities in such a way that: | | | | | | | | | | |
|--|--|--------------------|---------------------|--------------------------|--------|-------------|--|--|--|--|
| | | 5 | 4 | 3 | 2 | 1 | | | | |
| PSY 4_2 | Completed less than desirable | Never | Rarely | At times | Often | Permanently | | | | |
| PSY 4_5 | Doing work required extra effort or extra time | Never | Rarely | At times | Often | Permanently | | | | |
| OVER THE LAS | OVER THE LAST 4 WEEKS, did it happen that problems with memory, attention concentration or fast mental fatigue influenced your | | | | | | | | | |
| daily activities | in such a way that: | | | | | | | | | |
| | | 5 | 4 | 3 | 2 | 1 | | | | |
| PSY 4_8 | Did not do job or other tasks as accurately as usual | Never | Rarely | At times | Often | Permanently | | | | |
| PSY 4_9 | Doing work required extra effort or extra time | Never | Rarely | At times | Often | Permanently | | | | |
| FOR THE LAST | 4 WEEKS, to what extent did your em | otional state limi | t you in the follow | ving activities <u>:</u> | | | | | | |
| | | 5 | 4 | 3 | 2 | 1 | | | | |
| PSY 4_11 | In work (in professional activities, training or household chores) | Not at all | A bit | Moderately | Rather | Very much | | | | |
| PSY 4_14 | In your hobby, favorite activities | Not at all | A bit | Moderately | Rather | Very much | | | | |
| | | | | | | | | | | |

| Please answer the following questions about how you evaluate the change in your mood and mental performance. | | | | | | | | | |
|--|--|---------------------|-------------|-----------|--------------|----------------------|--|--|--|
| | | 1 | 2 | 3 | 4 | 5 | | | |
| PSY 5_5 | How do you assess your satisfaction with yourself and life now compared to year earlier? | Significantly worse | A bit worse | No change | A bit better | Significantly better | | | |
| PSY 5_6 | How do you assesse your memory, attention and mental performance now compared to year earlier? | Significantly worse | A bit worse | No change | A bit better | Significantly better | | | |

Annex 1

| Please answer how relevant the following statements consist to your point of view. | | | | | | | | | |
|--|---|---------------|--------------|---------------|--------------|---------------|--|--|--|
| a. | | 1 | 2 | 3 | 4 | 5 | | | |
| HTN_PSY_1 | Believe that I am healthy, and high blood pressure is not a disease and cannot be a cause for worry | Certainly yes | Probably yes | Tough to tell | Probably not | Certainly not | | | |
| b. | | 1 | 2 | 3 | 4 | 5 | | | |
| HTN_PSY_3 | I constantly think about how to fight against with hypertension (high blood pressure) | Certainly yes | Probably yes | Tough to tell | Probably not | Certainly not | | | |
| HTN_PSY_4 | I am depressed and worried by the idea that the treatment of hypertension (high blood pressure) should be constantly carried out | Certainly yes | Probably yes | Tough to tell | Probably not | Certainly not | | | |

COMBINED_SOC

| Please note how satisfied you are currently with | | | | | | | | | |
|--|----------------------------|----------------------|---------------------|---------------|----------------------|--------------------------|--|--|--|
| | | 5 | 4 | 3 | 2 | 1 | | | |
| SOC 1_1 | your financial situation | Completely satisfied | Rather satisfied | Tough to tell | Rather not satisfied | Completely not satisfied | | | |
| SOC 1_8 | recreational opportunities | Completely satisfied | Rather satisfied | Tough to tell | Rather not satisfied | Completely not satisfied | | | |

| Please answer the questions regarding your social environment. | | | | | | | |
|--|--|---------------|--------------|---------------|--------------|---------------|--|
| | | 1 | 2 | 3 | 4 | 5 | |
| SOC 2_3 | Do you always have the opportunity to get the information you need in everyday life? | Never | Rarely | At times | Often | Permanently | |
| SOC 2_5 | Do you often get information for everyday life from your friends, relatives (for example, about a good doctor, interesting film, etc.)? | Never | Rarely | At times | Often | Permanently | |
| SOC 2_8 | Do you feel that there are enough people around with whom you have a good relationship? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes | |

| a. Please and medical care | swer the questions regarding e availability for you. | 1 | 2 | 3 | 4 | 5 | |
|---|--|---------------|--------------|---------------|--------------|---------------|--|
| SOC 3_3 | Is the medical care you need available for you? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes | |
| HTN_SOC_3 | Are you satisfied with how your doctor treats hypertension (high blood pressure)? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes | |
| Please mark the appropriate answer describing the situation FOR THE LAST 4 WEEKS? | | | | | | | |
| b. | | 5 | 4 | 3 | 2 | 1 | |
| HTN_SOC_5 | How often did the pressure increase interfere you continuing a normal family, friendly conversation, or professional? | Never | Rarely | At times | Often | Very Often | |
| HTN_SOC_7 | How often did you have to put off your household or referral tasks for a while to tackle the blood pressure increase? | Never | Rarely | At times | Often | Very Often | |

COMBINED_THER

| a. Please a regarding you treatment. | answer the following questions r satisfaction with the | 1 | 2 | 3 | 4 | 5 |
|--------------------------------------|--|-------------------------|--------------------|---------------|--------------------|-------------------------|
| THER 1_1 | Are you satisfied with the treatment? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes |
| HTN_THER_1 | In your opinion, is the treatment of hypertension (high blood pressure) prescribed for you effective now? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes |
| HTN_THER_2 | In your opinion, is the treatment of hypertension (high blood pressure) prescribed for you required now? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes |
| | | 1 | 2 | 3 | 4 | 5 |
| THER 2_1 | How has your performance changed during/after treatment? | Significantly worsened | Worsened a bit | No change | Improved a bit | Significantly improved |
| THER 2_2 | How has your general state changed during/after treatment? | Significantly worsened | Worsened a bit | No change | Improved a bit | Significantly improved |
| THER 2_3 | The number and intensity of the symptoms during/after treatment | Significantly increased | Increased a bit | No change | Decreased a bit | Significantly decreased |

Annex 1

| | | 1 | 2 | 3 | 4 | 5 |
|------------|---|------------------------|-------------------|---------------|-------------------------|------------------------|
| THER 3_1 | How has your usual emotional state changed during/after treatment? | Significantly worsened | Worsened a bit | No change | Improved a bit | Significantly improved |
| | | 5 | 4 | 3 | 2 | 1 |
| THER 5_1 | Do you find the regimen of your prescribed medication too complicated? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes |
| THER 5_2 | Do you find the doctor's recommendations for lifestyle changing too complicated? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes |
| THER 5_3 | How difficult is it for you to follow the doctor's recommendations regarding medication and lifestyle changes? | Certainly easy | Rather easy | Tough to tell | Rather difficult | Very difficult |
| THER 5_6 | How often do you have side effects from medications prescribed by your doctor? | Never | Rarely | At times | Often | Permanently |
| THER 5_7 | How worried are you about the side effects of prescribed medications? | Do not worry | A bit | Moderately | Much | Extremely |
| b. | | 5 | 4 | 3 | 2 | 1 |
| HTN_THER_3 | How often do you keep from buying antihypertensive drugs prescribed by your doctor? | Never | Rarely | At times | Often | Permanently |
| HTN_THER_4 | How often have you missed taking antihypertensive drugs due to fear of side effects? | Never | Rarely | At times | Often | Very often |
| HTN_THER_5 | Can you independently replace the medications prescribed by your doctor? | Certainly not | Probably not | Tough to tell | Probably yes | Certainly yes |
| THER 6_6 | How often do you independently change the dosage of the prescribed medicine? | Never | Rarely | At times | Often | Permanently |
| THER 7_2 | Do you follow the doctor's recommendations regarding physical activity and exercise? | Yes always | Usually yes | At times | Rarely и selectively | No, never |
| THER 7_3 | Do you follow the doctor's recommendations regarding the diet regimen and composition? | Yes always | Usually yes | At times | Rarely и selectively | No, never |